Cybin Inc. (HELP)
| Market Cap | 490.29M +166.4% |
| Revenue (ttm) | n/a |
| Net Income | -148.00M |
| EPS | -4.25 |
| Shares Out | 61.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,825,255 |
| Open | 7.58 |
| Previous Close | 7.60 |
| Day's Range | 7.40 - 8.23 |
| 52-Week Range | 3.76 - 9.12 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 37.51 (+374.21%) |
| Earnings Date | Aug 12, 2026 |
About HELP
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central ne... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for HELP stock is "Strong Buy." The 12-month stock price target is $37.51, which is an increase of 374.21% from the latest price.
News
Helus Pharma initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Helus Pharma (HELP) with an Overweight rating and $16 price target The firm thinks COMP360 data provide validation for the company’s HLP003 in treatment-resistant dep...
Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003
Helus Pharma (HELP) has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder. APPROACH enrolled adults with moderate to severe MDD,…
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability dat...
Helus Pharma price target lowered to $45 from $48 at Guggenheim
Guggenheim lowered the firm’s price target on Helus Pharma (HELP) to $45 from $48 and keeps a Buy rating on the shares. The Eli Lilly (LLY) transaction for AtaiBeckley (ATAI)…
Helus Pharma price target lowered to $15 from $30 at Alliance Global
Alliance Global lowered the firm’s price target on Helus Pharma (HELP) to $15 from $30 and keeps a Buy rating on the shares, based on a sum-of-the-parts analysis. The firm…
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPO...
Helus Pharma price target lowered to $70 from $95 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Helus Pharma (HELP) to $70 from $95 and keeps a Buy rating on the shares. The setup into the Phase 3 APPROACH…
Helus Pharma price target lowered to $42 from $45 at Canaccord
Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Helus Pharma (HELP) to $42 from $45 and keeps a Buy rating on the shares. The firm noted its lead…
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1 , 2 ,3 , EMBRACE, for ...
Cybin Annual report: Q4 2026
Cybin has published its Q4 2026 annual report on June 29, 2026.
Cybin Earnings release: Q4 2026
Cybin released its Q4 2026 earnings on June 29, 2026, summarizing the period's financial results.
Cybin Slides: Corporate presentation
Cybin has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping min...
Helus Pharma prices 10.31M common shares at $4.85 in public offering
Helus Pharma (HELP) is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the company at an offering price of $4.85 per…
Helus Pharma says enrollment in APPROACH Phase 3 trial ‘progressing as planned’
Helus Pharma (HELP) announced that enrollment in the APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder is progressing as planned and has surpassed…
Helus Pharma™ Announces US$50 Million Underwritten Offering
NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping min...
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment -
Cybin Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The summit featured updates on novel serotonergic agonists for MDD and GAD, with HLP003 in phase III and top-line data expected by year-end. The company leverages established psychiatric infrastructure and maintains strong FDA engagement, targeting NDA submission in 2028.
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serot...
Cybin Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing novel serotonergic agonists for mental health, with a lead MDD program showing strong efficacy and durability, and a second program targeting anxiety. Regulatory support is robust, commercialization prospects are strong due to unique dosing and IP, and key phase III data is expected in Q4.
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT NEW YORK and TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a cli...
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), please note references to Veterans...
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: H...
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel seroton...
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serot...